Abstract 1029: The association of body mass index with risk of endometrial cancer subtypes: Pooled analysis in E2C2
Authors: Veronica Wendy Setiawan, Hannah P. Yang, Malcolm C. Pike, Susan McCann, Herbert Yu, Yong-Bing Xiang, Alicja Wolk, Nicolas Wentzensen, Noel S. Weiss, Penelope M. Webb, Piet A. van den Brandt, Koen van de Vijver, Pamela J. Thompson, Brian L. Strom, Amanda B. Spurdle, Xiao-ou Shu, Catherine Schairer, Carlotta Sacerdote, Thomas E. Rohan, Kim Robien, Harvey Risch, Fulvio Ricceri, Timothy R. Rebbeck, Radhai Rastogi, Jennifer Prescott, Silvia Polidoro, Yikyung Park, Sara H. Olson, Kirsten B. Moysich, Anthony B. Miller, Marjorie L. McCullough, Rayna K. Matsuno, Anthony M. Magliocco, Galina Lurie, Lingeng Lu, Jolanta Lissowska, Xiaolin Liang, James V. Lacey, Laurence N. Kolonel, Brian E. Henderson, Susan E. Hankinson, Niclas Håkansson, Marc T. Goodman, Mia M. Gaudet, Montserrat Garcia-Closas, Christine Friedenreich, Jo L. Freudenheim, Jennifer Doherty
Journal: Cancer Research (2012)

Abstract Excess body weight is a known risk factor for endometrial cancer but whether it differentially affects histological subtypes of endometrial cancer is unclear. The two proposed main subtypes are the “estrogen-dependent Type I” and “non estrogen-dependent and clinically aggressive Type II”. Little is known about risk factors for Type II tumors mainly because most epidemiologic studies lack sufficient cases to study these rare tumors separately. Here we examined the association between recent adult body mass index (BMI) and endometrial tumor subtypes in a pooled analysis of 25 studies in the Epidemiology of Endometrial Cancer Consortium (E2C2). Individual-level data from 10 cohort studies and 15 case-control studies provided a total of 14,409 endometrial cancer cases and 35,950 controls for this analysis. Cohort studies were analyzed using a nested case-control design. The majority of women were white (86%) and postmenopausal (83%). Endometrial cancer cases were classified into two subtypes: Type I (endometrioid adenocarcinomas, adenocarcinoma tubular, papillary adenocarcinomas, mucinous adenocarcinomas, adenocarcinomas with squamous metaplasia, n=13,286) and Type II (serous, squamous cell, small cell, mixed cell, n=1,123). The associations of BMI with the risk of tumor subtypes were evaluated by calculating odds ratios (OR) and 95% confidence intervals (95% CI) using polytomous logistic regression models. Potential confounders included in the analysis were age, race, parity, age at menarche, oral contraceptive (OC) use, menopausal hormone (PMH) use, and smoking status. BMI was positively associated with both Type I and Type II tumors, but the association was stronger for Type I than for Type II tumors (P value for the difference in OR between Type I and Type II was &amp;lt;0.0001). The OR associated with each five kg/m2 increase in BMI (OR5) was 1.58 (95% CI: 1.55, 1.62) for Type I and 1.35 (95% CI: 1.28, 1.42) for Type II. In the analysis of individual histologic types, the OR5 was lowest for serous tumors (1.28), moderate for mixed cell and clear cell (1.33-1.37), and highest for endometrioid tumors (1.60) and various adenocarcinoma groups (1.54-1.58). The associations of BMI with both Type I and II tumors were greater among postmenopausal women who never used PMH [OR5 = 1.84 (95% CI: 1.78, 1.89) for Type I and 1.48 (95% CI: 1.38, 1.58) for Type II] than among estrogen-only users [OR5 = 1.20 (95% CI: 1.13, 1.28) for Type I and 1.05 (95% CI: 0.87, 1.26) for Type II] or among estrogen-progestin users [OR5 = 1.33 (95% CI: 1.25, 1.41) for Type I and 1.12 (95% CI: 0.95, 1.33) for Type II]. Other known endometrial cancer risk factors such as OC use, parity, and smoking did not appear to modify the association between BMI and tumor subtype. In this large pooled analysis, we observed that BMI is a risk factor for all types of endometrial cancer, although, the association is consistently stronger for Type I than for Type II tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1029. doi:1538-7445.AM2012-1029